Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals is a commercial-stage biopharmaceutical company developing therapies for unmet medical needs in the US. They offer LUPKYNIS to treat adult lupus nephritis patients. They have a collaboration agreement with Otsuka Pharmaceutical Co., Ltd. Founded in 1993, Aurinia is headquartered in Edmonton, Canada.
Overview
Strengths
- Current Price to Earnings Ratio (7.04) is lower than the sector mean (91.15).
- The company has high returns. ROIC (20.68%) is higher than the sector mean (6.02%).
- EV/EBIT (17.02) is lower than the sector mean.
- Price to free cash flow (14.93) is lower than the sector mean.
- Strong EBITDA Margin of 49.31%.
Weaknesses
- With a depreciation Potential of -74.21%, based on our fundamental analysis, it suggests the stock may be overvalued.
- Analysts expect revenues to decline in the coming year.
- The company has high debt. Net Debt to EBITDA Ratio (100.00) is higher than the sector mean.
Key Financial Data